BZPEERPapers, people, evidence and research paths
Menu

Discover

SearchFind papers, people, topics, institutions and opportunities from one place.GraphSee how papers, authors, topics and evidence connect.

Research tools

HomeContinue from the papers, people and topics that matter now.CollectionsTurn saved papers into reading lists, evidence maps and shareable context.ResearchReconstruct the path that led you from search to paper to question.CollaborationMove from a paper, topic or expert request into a focused thread.PublishCreate full-text research articles with metadata, formulas and versions.

Network

ExpertsFind specialists whose work and reviews explain why they can help.CommunitiesJoin research groups organized around papers, topics and shared evidence.

Opportunities

ListingsBrowse roles, calls and collaborations connected to real research context.

Account

Log inReturn to your saved papers, graph views and active threads.Create accountStart saving papers, building a research trail and joining teams.
Log inCreate account

Source author record

Lorenzo Trippa

Lorenzo Trippa appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record
ApplicationsMethodologymath.STStatistics TheoryComputationMachine LearningQuantitative Methods

Catalog footprint

What is connected

14works
7topics
4close collaborators

Actions

Connect this record

Log in to claim
Open graphBrowse works

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

14 published item(s)

preprint2022arXiv

Bayesian Multi-Arm De-Intensification Designs

In recent years new cancer treatments improved survival in multiple histologies. Some of these therapeutics, and in particular treatment combinations, are often associated with severe treatment-related adverse events (AEs). It is therefore important to identify alternative de-intensified therapies, for example dose-reduced therapies, with reduced AEs and similar efficacy. We introduce a sequential design for multi-arm de-intensification studies. The design evaluates multiple de-intensified therapies at different dose levels, one at the time, based on modeling of toxicity and efficacy endpoints. We study the utility of the design in oropharynx cancer de-intensification studies. We use a Bayesian nonparametric model for efficacy and toxicity outcomes to define decision rules at interim and final analysis. Interim decisions include early termination of the study due to inferior survival of experimental arms compared to the standard of care (SOC), and transitions from one de-intensified treatment arm to another with a further reduced dose when there is sufficient evidence of non-inferior survival. We evaluate the operating characteristics of the design using simulations and data from recent de-intensification studies in human papillomavirus (HPV)-associated oropharynx cancer.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

Interpretable Model Summaries Using the Wasserstein Distance

Statistical models often include thousands of parameters. However, large models decrease the investigator's ability to interpret and communicate the estimated parameters. Reducing the dimensionality of the parameter space in the estimation phase is a commonly used approach, but less work has focused on selecting subsets of the parameters for interpreting the estimated model -- especially in settings such as Bayesian inference and model averaging. Importantly, many models do not have straightforward interpretations and create another layer of obfuscation. To solve this gap, we introduce a new method that uses the Wasserstein distance to identify a low-dimensional interpretable model projection. After the estimation of complex models, users can budget how many parameters they wish to interpret and the proposed generates a simplified model of the desired dimension minimizing the distance to the full model. We provide simulation results to illustrate the method and apply it to cancer datasets.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

Sensitivity Analyses of Clinical Trial Designs: Selecting Scenarios and Summarizing Operating Characteristics

The use of simulation-based sensitivity analyses is fundamental to evaluate and compare candidate designs for future clinical trials. In this context, sensitivity analyses are especially useful to assess the dependence of important design operating characteristics (OCs) with respect to various unknown parameters (UPs). Typical examples of OCs include the likelihood of detecting treatment effects and the average study duration, which depend on UPs that are not known until after the onset of the clinical study, such as the distributions of the primary outcomes and patient profiles. Two crucial components of sensitivity analyses are (i) the choice of a set of plausible simulation scenarios $\{\boldsymbolθ_1,...,\boldsymbolθ_K\}$ and (ii) the list of OCs of interest. We propose a new approach to choose the set of scenarios for inclusion in design sensitivity analyses. Our approach balances the need for simplicity and interpretability of OCs computed across several scenarios with the need to faithfully summarize -- through simulations -- how the OCs vary across all plausible values of the UPs. Our proposal also supports the selection of the number of simulation scenarios to be included in the final sensitivity analysis report. To achieve these goals, we minimize a loss function $\mathcal{L}(\boldsymbolθ_1,...,\boldsymbolθ_K)$ that formalizes whether a specific set of $K$ sensitivity scenarios $\{\boldsymbolθ_1,...,\boldsymbolθ_K\}$ is adequate to summarize how the OCs of the trial design vary across all plausible values of the UPs. Then, we use optimization techniques to select the best set of simulation scenarios to exemplify the OCs of the trial design.

0 citations0 reviewsNo code linkedOpen access
preprint2020arXiv

Bayesian Combinatorial Multi-Study Factor Analysis

Analyzing multiple studies allows leveraging data from a range of sources and populations, but until recently, there have been limited methodologies to approach the joint unsupervised analysis of multiple high-dimensional studies. A recent method, Bayesian Multi-Study Factor Analysis (BMSFA), identifies latent factors common to all studies, as well as latent factors specific to individual studies. However, BMSFA does not allow for partially shared factors, i.e. latent factors shared by more than one but less than all studies. We extend BMSFA by introducing a new method, Tetris, for Bayesian combinatorial multi-study factor analysis, which identifies latent factors that can be shared by any combination of studies. We model the subsets of studies that share latent factors with an Indian Buffet Process. We test our method with an extensive range of simulations, and showcase its utility not only in dimension reduction but also in covariance estimation. Finally, we apply Tetris to high-dimensional gene expression datasets to identify patterns in breast cancer gene expression, both within and across known classes defined by germline mutations.

0 citations0 reviewsNo code linkedOpen access
preprint2020arXiv

Combining Breast Cancer Risk Prediction Models

Accurate risk stratification is key to reducing cancer morbidity through targeted screening and preventative interventions. Numerous breast cancer risk prediction models have been developed, but they often give predictions with conflicting clinical implications. Integrating information from different models may improve the accuracy of risk predictions, which would be valuable for both clinicians and patients. BRCAPRO and BCRAT are two widely used models based on largely complementary sets of risk factors. BRCAPRO is a Bayesian model that uses detailed family history information to estimate the probability of carrying a BRCA1/2 mutation, as well as future risk of breast and ovarian cancer, based on mutation prevalence and penetrance (age-specific probability of developing cancer given genotype). BCRAT uses a relative hazard model based on first-degree family history and non-genetic risk factors. We consider two approaches for combining BRCAPRO and BCRAT: 1) modifying the penetrance functions in BRCAPRO using relative hazard estimates from BCRAT, and 2) training an ensemble model that takes as input BRCAPRO and BCRAT predictions. We show that the combination models achieve performance gains over BRCAPRO and BCRAT in simulations and data from the Cancer Genetics Network.

0 citations0 reviewsNo code linkedOpen access
preprint2020arXiv

Integration of Survival Data from Multiple Studies

We introduce a statistical procedure that integrates survival data from multiple biomedical studies, to improve the accuracy of predictions of survival or other events, based on individual clinical and genomic profiles, compared to models developed leveraging only a single study or meta-analytic methods. The method accounts for potential differences in the relation between predictors and outcomes across studies, due to distinct patient populations, treatments and technologies to measure outcomes and biomarkers. These differences are modeled explicitly with study-specific parameters. We use hierarchical regularization to shrink the study-specific parameters towards each other and to borrow information across studies. Shrinkage of the study-specific parameters is controlled by a similarity matrix, which summarizes differences and similarities of the relations between covariates and outcomes across studies. We illustrate the method in a simulation study and using a collection of gene-expression datasets in ovarian cancer. We show that the proposed model increases the accuracy of survival prediction compared to alternative meta-analytic methods.

0 citations0 reviewsNo code linkedOpen access
preprint2020arXiv

Optimality of testing procedures for survival data

Most statistical tests for treatment effects used in randomized clinical trials with survival outcomes are based on the proportional hazards assumption, which often fails in practice. Data from early exploratory studies may provide evidence of non-proportional hazards which can guide the choice of alternative tests in the design of practice-changing confirmatory trials. We study a test to detect treatment effects in a late-stage trial which accounts for the deviations from proportional hazards suggested by early-stage data. Conditional on early-stage data, among all tests which control the frequentist Type I error rate at a fixed $α$ level, our testing procedure maximizes the Bayesian prediction of the finite-sample power. Hence, the proposed test provides a useful benchmark for other tests commonly used in presence of non-proportional hazards, for example weighted log-rank tests. We illustrate the approach in a simulations based on data from a published cancer immunotherapy phase III trial.

0 citations0 reviewsNo code linkedOpen access
preprint2016arXiv

Robust Lineage Reconstruction from High-Dimensional Single-Cell Data

Single-cell gene expression data provide invaluable resources for systematic characterization of cellular hierarchy in multi-cellular organisms. However, cell lineage reconstruction is still often associated with significant uncertainty due to technological constraints. Such uncertainties have not been taken into account in current methods. We present ECLAIR, a novel computational method for the statistical inference of cell lineage relationships from single-cell gene expression data. ECLAIR uses an ensemble approach to improve the robustness of lineage predictions, and provides a quantitative estimate of the uncertainty of lineage branchings. We show that the application of ECLAIR to published datasets successfully reconstructs known lineage relationships and significantly improves the robustness of predictions. In conclusion, ECLAIR is a powerful bioinformatics tool for single-cell data analysis. It can be used for robust lineage reconstruction with quantitative estimate of prediction accuracy.

0 citations0 reviewsNo code linkedOpen access
preprint2015arXiv

Bayesian nonparametric cross-study validation of prediction methods

We consider comparisons of statistical learning algorithms using multiple data sets, via leave-one-in cross-study validation: each of the algorithms is trained on one data set; the resulting model is then validated on each remaining data set. This poses two statistical challenges that need to be addressed simultaneously. The first is the assessment of study heterogeneity, with the aim of identifying a subset of studies within which algorithm comparisons can be reliably carried out. The second is the comparison of algorithms using the ensemble of data sets. We address both problems by integrating clustering and model comparison. We formulate a Bayesian model for the array of cross-study validation statistics, which defines clusters of studies with similar properties and provides the basis for meaningful algorithm comparison in the presence of study heterogeneity. We illustrate our approach through simulations involving studies with varying severity of systematic errors, and in the context of medical prognosis for patients diagnosed with cancer, using high-throughput measurements of the transcriptional activity of the tumor's genes.

0 citations0 reviewsNo code linkedOpen access
preprint2015arXiv

Looking-backward probabilities for Gibbs-type exchangeable random partitions

Gibbs-type random probability measures and the exchangeable random partitions they induce represent the subject of a rich and active literature. They provide a probabilistic framework for a wide range of theoretical and applied problems that are typically referred to as species sampling problems. In this paper, we consider the class of looking-backward species sampling problems introduced in Lijoi et al. (Ann. Appl. Probab. 18 (2008) 1519-1547) in Bayesian nonparametrics. Specifically, given some information on the random partition induced by an initial sample from a Gibbs-type random probability measure, we study the conditional distributions of statistics related to the old species, namely those species detected in the initial sample and possibly re-observed in an additional sample. The proposed results contribute to the analysis of conditional properties of Gibbs-type exchangeable random partitions, so far focused mainly on statistics related to those species generated by the additional sample and not already detected in the initial sample.

0 citations0 reviewsNo code linkedOpen access
preprint2014arXiv

Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials

Targeted therapies based on biomarker profiling are becoming a mainstream direction of cancer research and treatment. Depending on the expression of specific prognostic biomarkers, targeted therapies assign different cancer drugs to subgroups of patients even if they are diagnosed with the same type of cancer by traditional means, such as tumor location. For example, Herceptin is only indicated for the subgroup of patients with HER2+ breast cancer, but not other types of breast cancer. However, subgroups like HER2+ breast cancer with effective targeted therapies are rare and most cancer drugs are still being applied to large patient populations that include many patients who might not respond or benefit. Also, the response to targeted agents in human is usually unpredictable. To address these issues, we propose SUBA, subgroup-based adaptive designs that simultaneously search for prognostic subgroups and allocate patients adaptively to the best subgroup-specific treatments throughout the course of the trial. The main features of SUBA include the continuous reclassification of patient subgroups based on a random partition model and the adaptive allocation of patients to the best treatment arm based on posterior predictive probabilities. We compare the SUBA design with three alternative designs including equal randomization, outcome-adaptive randomization and a design based on a probit regression. In simulation studies we find that SUBA compares favorably against the alternatives.

0 citations0 reviewsNo code linkedOpen access
preprint2013arXiv

Bayesian nonparametric analysis of reversible Markov chains

We introduce a three-parameter random walk with reinforcement, called the $(θ,α,β)$ scheme, which generalizes the linearly edge reinforced random walk to uncountable spaces. The parameter $β$ smoothly tunes the $(θ,α,β)$ scheme between this edge reinforced random walk and the classical exchangeable two-parameter Hoppe urn scheme, while the parameters $α$ and $θ$ modulate how many states are typically visited. Resorting to de Finetti's theorem for Markov chains, we use the $(θ,α,β)$ scheme to define a nonparametric prior for Bayesian analysis of reversible Markov chains. The prior is applied in Bayesian nonparametric inference for species sampling problems with data generated from a reversible Markov chain with an unknown transition kernel. As a real example, we analyze data from molecular dynamics simulations of protein folding.

0 citations0 reviewsNo code linkedOpen access
preprint2013arXiv

Defining Predictive Probability Functions for Species Sampling Models

We review the class of species sampling models (SSM). In particular, we investigate the relation between the exchangeable partition probability function (EPPF) and the predictive probability function (PPF). It is straightforward to define a PPF from an EPPF, but the converse is not necessarily true. In this paper we introduce the notion of putative PPFs and show novel conditions for a putative PPF to define an EPPF. We show that all possible PPFs in a certain class have to define (unnormalized) probabilities for cluster membership that are linear in cluster size. We give a new necessary and sufficient condition for arbitrary putative PPFs to define an EPPF. Finally, we show posterior inference for a large class of SSMs with a PPF that is not linear in cluster size and discuss a numerical method to derive its PPF.

0 citations0 reviewsNo code linkedOpen access
preprint2011arXiv

False discovery rates in somatic mutation studies of cancer

The purpose of cancer genome sequencing studies is to determine the nature and types of alterations present in a typical cancer and to discover genes mutated at high frequencies. In this article we discuss statistical methods for the analysis of somatic mutation frequency data generated in these studies. We place special emphasis on a two-stage study design introduced by Sjöblom et al. [Science 314 (2006) 268--274]. In this context, we describe and compare statistical methods for constructing scores that can be used to prioritize candidate genes for further investigation and to assess the statistical significance of the candidates thus identified. Controversy has surrounded the reliability of the false discovery rates estimates provided by the approximations used in early cancer genome studies. To address these, we develop a semiparametric Bayesian model that provides an accurate fit to the data. We use this model to generate a large collection of realistic scenarios, and evaluate alternative approaches on this collection. Our assessment is impartial in that the model used for generating data is not used by any of the approaches compared. And is objective, in that the scenarios are generated by a model that fits data. Our results quantify the conservative control of the false discovery rate with the Benjamini and Hockberg method compared to the empirical Bayes approach and the multiple testing method proposed in Storey [J. R. Stat. Soc. Ser. B Stat. Methodol. 64 (2002) 479--498]. Simulation results also show a negligible departure from the target false discovery rate for the methodology used in Sjöblom et al. [Science 314 (2006) 268--274].

0 citations0 reviewsNo code linkedOpen access